Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data


Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.

Aim(s): We performed the immunoprofiling of ATRX and DAXX and the assessment of ALT status in a series of 142 PNET patients followed at 1 Turkish and 3 Portuguese Hospital Centers, and correlated the results with the respective clinical-pathological data.

Materials and methods: Immunohistochemistry assays were performed for both antibodies and telomere-FISH was performed in the negative-stained cases. According to the extension of positive nuclear staining, cases were considered negative (< 10%), positive (> 80%) or “mosaic” (10-80%) for both proteins.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Gaspar T, Pinheiro J, Canberk S, İnce , Tokat F,

Keywords: pancreas, pancreatic neuroendocrine tumors, PNETs, ATRX, DAXX, ALT, mosaic,

To read the full abstract, please log into your ENETS Member account.